top of page

BIO-Europe 2026: Bionyra Pharma emerged from stealth earlier this year with $165m in series A financing and three in-licensed assets: a TL1A Mab, a TL1A*IL-23p19 bispecific, and an IL-25 Mab

3 hours ago
1 min read

CEO and co-founder Frédéric Marrache tells us that half-life extension technology should bestow important differentiation on the company’s TL1A assets, versus more advanced, similar projects in development elsewhere. He also believes that IL-25 could become an important new mechanism for atopic dermatitis.




Coverage brought to you by



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@Biotech.TV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Mispro_Logo_2023_Primary-4.png

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

Learn more

bottom of page